share_log

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $20

Benzinga ·  Mar 13 12:04

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the price target from $25 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 275
Write a comment